Ultra‐hypofractionated radiation therapy for unfavourable intermediate‐risk and high‐risk prostate cancer is safe and effective: 5‐year outcomes of a phase II trial

Abstract

ObjectivesTo report toxicity (primary endpoint) and biochemical disease-free survival (BDFS) outcomes of a phase II trial evaluating ultra-hypofractionated radiation therapy (UHRT), focusing on patients with unfavourable intermediate-risk and high-risk prostate cancer (PCa). Patients and MethodsFrom 2012 to 2017, 154 patients (92 with unfavourable intermediate-risk or high-risk PCa) were treated with helical TomoTherapy delivering 43.8-45.2 Gy in eight fractions over 3 weeks. Of these, 73% received hormonotherapy (51% neoadjuvant). ResultsThe median (range) follow-up was 48 (19-84) months. For the whole series, crude BDFS and 5-year BDFS rates were 97.4% and 94.3%, respectively. The corresponding figures for unfavourable intermediate-risk and high-risk PCa were 96.7% and 90%, respectively. The crude metastasis-free survival rate was 98% for the unfavourable intermediate-risk and high-risk group. For the whole series, the 5-year cumulative urinary/ intestinal grade 2+ late toxicity was 17.8/7.4%. No grade 4-5 toxicity was observed. One patient experienced late grade 3 toxicity (urinary). ConclusionThis eight-fraction UHRT regimen can be safely delivered to patients with unfavourable intermediate-risk/high-risk PCa. Its relapse rates are similar to those reported for the combination of external beam radiotherapy plus brachytherapy, however, the observed toxicity profile is milder. The disease survival rates compare favourably with historical controls in some other forms of radiotherapy, with similar side effects. Since the low rate of biochemical/ metastasis relapse is encouraging, further research to confirm these results is justified.Keywords stereotactic body radiotherapy, brachytherapy, high risk, hypofractionated radiotherapy, quality of life, #ProstateCancer, #PCSM

Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer

“…Among them, radiotherapy is one of the main treatment methods for organ-confined and locally advanced prostate cancer, along with hormone therapy and surgery. And it has an irreplaceable role in improving the survival rate, prolonging the survival time and reducing complaints of patients with prostate cancer [7][8][9]. For high-risk prostate cancer (clinical T1-4N0-1M0), radical radiotherapy combined with endocrine therapy can achieve the same efficacy as surgery [10].…”

Proton versus photon therapy for high-risk prostate cancer with dose escalation of dominant intraprostatic lesions: a preliminary planning study

“…mpMRI-defined DILs are highly correlated to the location and size of the histopathologically proven tumor on wholemount prostatectomy specimens with high levels of clonogenic cell density (3). The delivery of an escalated dose to the whole prostate has reportedly improved biochemical disease-free survival (bDFS); however, the associated rates of gastrointestinal (GI) and genitourinary (GU) toxicity are higher (4,5). The application of a simultaneous integrated boost (SIB) technique allows the delivery of an escalated dose to the DILs while respecting the planning constraints of the organs at risk (OARs) (6,7).…”